Quarterly Consolidated Statement Of Cash Flows

STELLA PHARMA CORPORATION - Filing #7299803

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
As at
2023-03-31
Quarterly consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-267,279,000 JPY
-304,430,000 JPY
Depreciation
17,944,000 JPY
17,600,000 JPY
Interest and dividend income
-105,000 JPY
-5,000 JPY
Interest expenses
1,683,000 JPY
1,061,000 JPY
Decrease (increase) in trade receivables
-42,348,000 JPY
-42,348,000 JPY
Decrease (increase) in inventories
17,034,000 JPY
32,167,000 JPY
Increase (decrease) in trade payables
-75,690,000 JPY
-49,069,000 JPY
Subtotal
548,549,000 JPY
-433,507,000 JPY
Interest paid
-1,683,000 JPY
-1,061,000 JPY
Income taxes paid
-2,786,000 JPY
-2,850,000 JPY
Net cash provided by (used in) operating activities
545,793,000 JPY
-435,804,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-3,801,000 JPY
-10,578,000 JPY
Net cash provided by (used in) investing activities
88,185,000 JPY
-10,578,000 JPY
Cash flows from financing activities
Repayments of long-term borrowings
-80,004,000 JPY
-80,004,000 JPY
Proceeds from issuance of shares
946,139,000 JPY
388,258,000 JPY
Purchase of treasury shares
-26,000 JPY
JPY
Net cash provided by (used in) financing activities
865,559,000 JPY
308,339,000 JPY
Net increase (decrease) in cash and cash equivalents
1,499,538,000 JPY
-138,043,000 JPY
Cash and cash equivalents
3,511,772,000 JPY
2,012,233,000 JPY
2,531,683,000 JPY
2,669,727,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.